214 related articles for article (PubMed ID: 16706826)
41. Role of iron in the natural history and clinical course of hepatitis C disease.
Shedlofsky SI
Hepatogastroenterology; 1998; 45(20):349-55. PubMed ID: 9638405
[TBL] [Abstract][Full Text] [Related]
42. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.
Bortolami M; Kotsafti A; Cardin R; Farinati F
J Viral Hepat; 2008 Jul; 15(7):515-22. PubMed ID: 18331250
[TBL] [Abstract][Full Text] [Related]
43. Analyses for binding of the transferrin family of proteins to the transferrin receptor 2.
Kawabata H; Tong X; Kawanami T; Wano Y; Hirose Y; Sugai S; Koeffler HP
Br J Haematol; 2004 Nov; 127(4):464-73. PubMed ID: 15521925
[TBL] [Abstract][Full Text] [Related]
44. Fibronectin levels in chronic viral hepatitis and response of this protein to interferon therapy.
Kandemir O; Polat G; Sahin E; Bagdatoglu O; Camdeviren H; Kaya A
Hepatogastroenterology; 2004; 51(57):811-4. PubMed ID: 15143922
[TBL] [Abstract][Full Text] [Related]
45. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
[TBL] [Abstract][Full Text] [Related]
46. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
[TBL] [Abstract][Full Text] [Related]
47. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
[TBL] [Abstract][Full Text] [Related]
48. Predictive value of the phosphorylation of signal transducers and activators of transcription in the outcome of interferon therapy for chronic hepatitis C.
Miyaaki H; Ichikawa T; Nakao K; Takeshita S; Shibata H; Ozawa E; Akiyama M; Miuma S; Eguchi K
Intervirology; 2008; 51(6):394-9. PubMed ID: 19258717
[TBL] [Abstract][Full Text] [Related]
49. Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver.
Kakizaki S; Takagi H; Ichikawa T; Abe T; Yamada T; Suzuki K; Kojima A; Takayama H; Takezawa J; Nagamine T; Mori M
Biol Trace Elem Res; 2000 Feb; 73(2):151-62. PubMed ID: 11049207
[TBL] [Abstract][Full Text] [Related]
50. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
51. Regulation of transferrin receptor 2 in human cancer cell lines.
Calzolari A; Finisguerra V; Oliviero I; Deaglio S; Mariani G; Malavasi F; Testa U
Blood Cells Mol Dis; 2009; 42(1):5-13. PubMed ID: 19019709
[TBL] [Abstract][Full Text] [Related]
52. Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C.
Horiike S; Kawanishi S; Kaito M; Ma N; Tanaka H; Fujita N; Iwasa M; Kobayashi Y; Hiraku Y; Oikawa S; Murata M; Wang J; Semba R; Watanabe S; Adachi Y
J Hepatol; 2005 Sep; 43(3):403-10. PubMed ID: 16023246
[TBL] [Abstract][Full Text] [Related]
53. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
Chehadeh W; Al-Nakib W
J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
[TBL] [Abstract][Full Text] [Related]
54. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin.
Lin CC; Yin MC
Clin Nutr; 2009 Feb; 28(1):34-8. PubMed ID: 19042060
[TBL] [Abstract][Full Text] [Related]
55. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
56. Steatosis correlates with hepatic expression of death receptors and activation of nuclear factor-kappaB in chronic hepatitis C.
Hung CH; Lee CM; Kuo FY; Jiang SR; Hu TH; Chen CH; Wang JH; Lu SN; Eng HL; Changchien CS
Liver Int; 2008 Mar; 28(3):339-46. PubMed ID: 18290776
[TBL] [Abstract][Full Text] [Related]
57. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
[TBL] [Abstract][Full Text] [Related]
58. 8-Hydroxy-2'-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Chuma M; Hige S; Nakanishi M; Ogawa K; Natsuizaka M; Yamamoto Y; Asaka M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1431-6. PubMed ID: 18854000
[TBL] [Abstract][Full Text] [Related]
59. Failure to respond to interferon-alpha 2a therapy is associated with increased hepatic iron levels in patients with chronic hepatitis C.
Kageyama F; Kobayashi Y; Murohisa G; Shimizu E; Suzuki F; Kikuyama M; Souda K; Kawasaki T; Nakamura H
Biol Trace Elem Res; 1998; 64(1-3):185-96. PubMed ID: 9845473
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical demonstration of transferrin receptor 1 and 2 in human hepatocellular carcinoma tissue.
Sakurai K; Sohda T; Ueda S; Tanaka T; Hirano G; Yokoyama K; Morihara D; Aanan A; Takeyama Y; Irie M; Iwata K; Syakado S; Noritomiz T; Yamashita Y; Sakisaka S
Hepatogastroenterology; 2014; 61(130):426-30. PubMed ID: 24901155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
